Ovintiv Inc. (OVV)

Revenue growth above 1.5x VET's 5.59%. David Dodd would confirm if the firm has a unique advantage driving sales higher.

Gross profit growth above 1.5x VET's 7.45%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.

EBIT growth above 1.5x VET's 14.37%. David Dodd would confirm if core operations or niche positioning yield superior profitability.

Operating income growth above 1.5x VET's 14.37%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.

Positive net income growth while VET is negative. John Neff might see a big relative performance advantage.

Positive EPS growth while VET is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.

Positive diluted EPS growth while VET is negative. John Neff might view this as a strong relative advantage in controlling dilution.

Dividend growth of 18.14% while VET is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.

Positive OCF growth while VET is negative. John Neff would see this as a clear operational advantage vs. the competitor.

Positive FCF growth while VET is negative. John Neff would see a strong competitive edge in net cash generation.

3Y revenue/share CAGR 1.25-1.5x VET's 104.23%. Bruce Berkowitz might see better product or regional expansions than the competitor.

5Y OCF/share CAGR above 1.5x VET's 6.13%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.

Positive 3Y OCF/share CAGR while VET is negative. John Neff might see a big short-term edge in operational efficiency.

Positive 10Y CAGR while VET is negative. John Neff might see a substantial advantage in bottom-line trajectory.

Positive 5Y CAGR while VET is negative. John Neff might view this as a strong mid-term relative advantage.

Positive short-term CAGR while VET is negative. John Neff would see a clear advantage in near-term profit trajectory.

5Y equity/share CAGR 1.25-1.5x VET's 107.93%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.

3Y equity/share CAGR 1.25-1.5x VET's 88.26%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.

Dividend/share CAGR of 19.22% while VET is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.

Dividend/share CAGR of 19.22% while VET is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.

3Y dividend/share CAGR of 19.22% while VET is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.

Our AR growth while VET is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.

Inventory is declining while VET stands at 68.41%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.

Positive asset growth while VET is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.

Positive BV/share change while VET is negative. John Neff sees a clear edge over a competitor losing equity.

We’re deleveraging while VET stands at 8.89%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.

No Data available this quarter, please select a different quarter.

We cut SG&A while VET invests at 33.32%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.